ReviewJournal of the Formosan Medical Association = Taiwan yi zhi2014
The receptor binding domain of MERS-CoV: the dawn of vaccine and treatment development.
Review in Journal of the Formosan Medical Association = Taiwan yi zhi, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The enzymes in COVID-19: A review.Biochimie · 2022Review
- Review
- Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.AAPS PharmSciTech · 2021Review
- H2V: a database of human genes and proteins that respond to SARS-CoV-2, SARS-CoV, and MERS-CoV infection.BMC bioinformatics · 2021Article
- Nanomedicine strategies to target coronavirus.Nano today · 2020Review
- Interplays between inflammasomes and viruses, bacteria (pathogenic and probiotic), yeasts and parasites.Immunology letters · 2020Review
- Article
- Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic.Frontiers in pharmacology · 2020Review
- Recombinant adenoviral vaccine encoding the spike 1 subunit of theVeterinary world · 2019Article
- Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection.Emerging microbes & infections · 2019Article
- Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.Viruses · 2017Article
- MERS and the dromedary camel trade between Africa and the Middle East.Tropical animal health and production · 2016Article
- The prevalence, origin, and prevention of six human coronaviruses.Virologica Sinica · 2016Article
- Middle East respiratory syndrome coronavirus "MERS-CoV": current knowledge gaps.Paediatric respiratory reviews · 2015Review
- Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives.PLoS pathogens · 2014Review
- MERS-CoV: Bridging the Knowledge Gaps.Oman medical journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another "SARS-like" threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.